

Cutaneous manifestations of antiphospholipid syndrome: a review of the clinical features, diagnosis and management

Teresa Pinto-Almeida¹, Mónica Caetano^{1,2}, Madalena Sanches¹, Manuela Selores^{1,2}

ACTA REUMATOL PORT. 2013;38:10-18

ABSTRACT

Antiphospholipid syndrome is a relatively recent systemic autoimmune disorder defined by thrombotic events and/or obstetric complications in the presence of persistent elevated antiphospholipid antibodies. It is characterized by a wide spectrum of clinical presentations and virtually any organ system or tissue may be affected by the consequences of vascular occlusion. Diagnosis is sometimes difficult and although classification criteria have been published and revised there remain ongoing issues regarding nomenclature, expanding clinical features, laboratory tests and management and much still has to be done. Cutaneous manifestations are common and frequently the first sign of the disease. Although extremely diverse it's important to know which dermatological findings should prompt consideration of antiphospholipid syndrome and the appropriate management for those patients. Much has been debated about when to consider antiphospholipid syndrome and consensus still does not exist, however in spite of being a diagnostic challenge clinicians should know when to look for antiphospholipid antibodies since an early diagnosis is important to prevent further and serious complications. In this article we focus on the cutaneous features that should raise suspicion on the presence of antiphospholipid syndrome and on the complex management of such patients. Many other dermatological signs related to this syndrome have been described in the literature but only occasionally and without consistency or statistic impact and therefore will not be considered here.

Keywords: Antiphospholipid Syndrome; Skin; Dermatology; Review; Diagnosis.

RESUMO

O síndrome antifosfolipídico é uma patologia auto-imune relativamente recente definida por eventos trombóticos e/ou complicações obstétricas na presença de anticorpos antifosfolípido elevados persistentes. Caracteriza-se por um vasto leque de apresentações clínicas e virtualmente qualquer sistema orgânico ou tecido pode ser afectado por oclusão vascular. O diagnóstico é por vezes difícil e, apesar de critérios de classificação terem sido publicados e revistos, muitas dúvidas persistem relativamente à nomenclatura, características clínicas, testes laboratoriais e abordagem destes doentes. As manifestações cutâneas são comuns e, frequentemente, o primeiro sinal da doença. Apesar da grande variabilidade, é importante reconhecer os achados dermatológicos que devem levantar a suspeita de um síndrome antifosfolipídico, assim como a abordagem adequada destes doentes. Muito tem sido debatido sobre quando considerar o diagnóstico desta entidade, não havendo ainda consenso neste assunto; no entanto, apesar de ser um desafio diagnóstico, é importante saber quando investigar a presença de anticorpos antifosfolípidos, uma vez que um diagnóstico precoce é crucial para prevenir complicações futuras graves. No presente artigo os autores descrevem as manifestações dermatológicas que devem fazer considerar o diagnóstico com enfoque na abordagem complexa destes doentes. Têm sido descritas na literatura muitas outras alterações cutâneas relacionadas com esta entidade, no entanto, apenas de forma ocasional e sem consistência ou impacto estatístico, pelo que não serão consideradas.

Palavras-chave: Síndrome Antifosfolipídico; Pele; Dermatologia; Revisão; Diagnóstico.

1. Serviço de Dermatologia, Hospital de Santo António – Centro Hospitalar do Porto, Porto, Portugal

2. Instituto de Ciências Biomédicas Abel Salazar – Universidade de Porto, Porto, Portugal

INTRODUCTION

Antiphospholipid syndrome (APS) is a relatively recent

autoimmune disorder defined by thrombotic events and/or obstetric morbidity in the presence of persistent elevated antiphospholipid antibodies (aPL), such as anticardiolipin antibodies (aCL), lupus anticoagulant (LA) and anti 2-glycoprotein I (aGPI). First described by Hughes et al in the early 80s there remain ongoing issues regarding nomenclature, clinical features, laboratory tests and management and much still has to be done¹⁻³. Cutaneous manifestations are common and may occur as the presenting sign⁴. Although heterogeneous it is important to know which dermatological findings should prompt consideration of APS and the appropriate management of those patients, hence the unique role of dermatologists in recognizing this disease⁵. Much has been debated about when to consider APS and consensus still does not exist. However in spite of being a diagnostic challenge, physicians should be familiar with these cutaneous features since an early diagnosis is important to prevent further complications.

ANTIPHOSPHOLIPID SYNDROME

APS is traditionally referred to as primary when there is no evidence of other pathologic condition. This subgroup is thought to be slightly more prevalent⁶. Secondary APS occurs in association with other diseases, most often systemic lupus erythematosus (SLE), but also in the context of other autoimmune, malignant, drug-induced and infectious diseases⁷. Features of APS are numerous depending on the size and location of the vessels involved and are explained by vascular occlusion. Catastrophic APS occurs when acute widespread organ and tissue infarctions develop leading to multiorgan failure. It accounts for less than 1% of cases, with a mortality rate of over 50%. Cutaneous manifestations are present in up to 70 %^{6,8,9}.

EPIDEMIOLOGY

The real prevalence of APS is unknown⁷. Antiphospholipid antibodies can be found in 1-5% of healthy young adults. Their clinical importance in this setting is unknown but they are thought to be of low titer and transient, therefore not increasing the risk of thrombosis¹⁰. Primary APS is more frequent in women (2:1 to 5:1)¹¹. This ratio is higher in secondary forms⁶. APS affects mostly young and middle-aged adults with 85% of patients between 15 and 50 years of age and a mean age at diagnosis of 34 years⁶.

DIAGNOSIS

Clinical and laboratory criteria must be present for diag-

nosing APS. The broad spectrum of clinical presentations and poorly standardized laboratory tests make the diagnosis a challenge in a wide range of specialties.

Since the formulation of the Sapporo classification criteria for APS in 1999, efforts have been made to better codify the diagnosis and an update on these criteria was published in 2006¹²⁻¹⁴. At least one clinical criteria and one laboratory criteria must be present. According to Miyakis et al clinical criteria are: 1 - vascular thrombosis (≥ 1 episode of thrombosis in any tissue or organ, objectively confirmed by imaging studies or histopathology, without significant evidence of inflammation in the vessel wall); 2 - pregnancy morbidity (≥ 1 unexplained deaths of a normal fetus at or beyond the 10th week of gestation, or ≥ 1 premature births of a normal neonate before the 34th week of gestation due to eclampsia or severe pre-eclampsia or placental insufficiency, or ≥ 3 unexplained consecutive spontaneous abortions before the 10th week of gestation, without maternal anatomic or hormonal abnormalities and chromosomal causes excluded)¹⁴. Laboratory criteria rely on the presence of medium-high titers of aCL, aGPI and/or LA, on ≥ 2 occasions at least 12 weeks apart, detected according to international guidelines and standardized procedures¹⁵⁻¹⁹. Although the attempts for standardization, these criteria are still on debate and much has to be done to improve their reproducibility in order to avoid misclassification and overdiagnosis²⁰⁻²⁵.

CUTANEOUS MANIFESTATIONS

Many dermatologic features have been described in association with APS. Although nonspecific and not included in the classification criteria, they are common and may be the presenting signs, providing an important clue for the diagnosis. Therefore, physicians should be familiar with the cutaneous presentations that should prompt consideration of APS. Given the lack of specificity and the similar features shared with other vascular occlusion syndromes, other causes must be excluded first. On the other hand it is important for dermatologists to be knowledgeable about APS as they can provide crucial information to uncover or confirm APS and early diagnosis will spare patients from more serious consequences of this disease.

In the first reports, dermatologic findings were found to occur in 4-55% of patients with APS²⁶⁻²⁸. This large variation was probably due to the lack of routine dermatologic examination²⁹. The first large study related to aPL was a retrospective one involving 295 patients with circulating LA³⁰. Forty-one percent had skin

lesions related to the coagulation defect as the first sign of the disease and nearly 40% of these had thrombotic events in the course of the disease, highlighting the importance of skin lesions as a marker for diagnosis and for more extensive involvement⁴. Cervera *et al.* found skin involvement in 36 of 100 patients with infection--related APS³¹. In a study of 200 patients with APS, dermatologic manifestations were noted in 49% and were the presenting sign in 30%²⁹. Diógenes *et al.* reported cutaneous features as the main complaint in 40% of 39 APS patients³².

LIVEDO

Livedo reticularis (LR) is the most frequent cutaneous manifestation of APS (Fig. 1). In spite of this strong association, the nonspecific nature should be reminded, as it occurs in a variety of physiologic and pathologic states³³. In the aforementioned update on the classification criteria for APS it was defined as the persisting, not reversible with rewarming, violaceous, red or blue, reticular or mottled pattern of the skin¹⁴. It may consist of regular unbroken circles (regular LR) or irregular-broken circles (livedo racemosa). The latter is more distinctive and is considered an independent, additive thrombotic risk factor^{6,29,34}. In a cohort of 1.000 European patients with APS, LR was the presenting manifestation in 20.4% and its overall prevalence was 24.1%, being higher in SLE-associated APS, in women and lower in the elderly⁶. Francès *et al.* reported similar results: LR occurred in 25.5% of patients and was the presentation sign in 17.5%²⁹. In a European multicentre study, a high prevalence was also found in primary APS (24%) and SLE-related APS (20%)²⁷. Another study of SLE-related APS found LR in 70% of patients, being the presenting sign in 40%³⁴. The association of LR and ischemic cerebrovascular events was first described by Sneddon in 1965³⁵. Sneddon's syndrome (SNS) is a rare but severe condition affecting mostly young and middle-aged women with the first cerebrovascular event occurring before 45 years of age. Livedo may precede the stroke by years. Since its description, it has been suggested that a subset of these patients have APS, predominantly manifested as cutaneous and cerebral vascular lesions³⁶⁻³⁹. The prevalence of aPL in SNS is variable, ranging from 40% to 50% in most series.^{34,40} This relationship is not fully understood. Some believe SNS could be regarded as APS and fall into this nosological entity^{41,42}. Others defend that aPL-negative and -positive patients with SNS belong to close but different subsets of this syndrome and should



FIGURE 1. Clinical features of livedo reticularis in a patient with APS

be regarded as similar clinical expression of two distinct disorders^{40,43}. Another group advocate that there is distinctive clinical, histologic and laboratory evidence to favour their separation in different disorders⁴⁴.

CUTANEOUS NECROSIS AND NECROTIC SKIN ULCERS

Cutaneous necrosis in APS is similar to that observed in other microvascular occlusion syndromes⁴⁵. The acute onset of a retiform noninflammatory necrotizing purpura is followed by a black necrotic plaque with active purpuric borders and bullous lesions. This may remain localized or become widespread⁴⁶⁻⁵¹. It is considered a major thrombotic event so long-term anticoagulation is warranted. Cervera *et al.* found cutaneous necrosis in 2.1% of patients⁶. Francès *et al.* described circumscribed cutaneous necrosis in 3.5% of patients and the extensive form in 2%²⁹. Cutaneous necrosis was reported in 3% of patients with circulating LA³⁰.

Necrotic skin ulcers are common and may be second after livedo in frequency (Fig. 2). Cervera *et al.* observed these ulcerations as the presenting feature in



FIGURE 2. Necrotic skin ulcers on the leg of an APS patient

3.9% of 1000 APS patients with an overall prevalence of 5.5%, usually located on the extremities⁶. Francès *et al* detected necrotic skin ulcerations in 3.5% of cases, manifesting early in the disease²⁹. Leg ulceration was found in 39% of patients with SLE and LA, compared to 24% of patients with SLE without LA³². In this case however the specific role of the aPL becomes less clear. Large ulcers resembling pyoderma gangrenosum have also been reported, though lacking the typical undermined borders and granulation tissue^{4,51,53}. Recalcitrant APS-related ulcers are also not uncommon^{54,55}.

DIGITAL GANGRENE

Digital gangrene is a common feature among APS patients, generally preceded by digital ischemic symptoms (Fig. 3). It is a major thrombotic event sometimes leading to amputation of digits and therefore requiring full anticoagulation^{29,36,57}. According to the literature, the overall prevalence ranges from 3.3% to 7.5%, manifesting as the presenting sign in 1.9-2.5% of individuals, and with no significant differences between primary and secondary forms of APS^{6,26,29}.

SUBUNGUAL SPLINTER HEMORRHAGES

Multiple subungual splinter hemorrhages may be a clinical feature of APS^{59,60}. Usually its sudden onset is concurrent with other thrombotic events leading to a probable underestimation of this condition, as shown by the low prevalence reported in most series, ranging from 0.7% to 5%^{6,29}.

PSEUDOVASCULITIC LESIONS

Pseudovasculitic lesions require a high index of suspicion. They mimic cutaneous vasculitis and may be misdiagnosed if a biopsy is not performed, leading to incor-



FIGURE 3. Highlight of digital gangrene on the fingers of a patient later diagnosed with APS

rect management and exposure to potentially deleterious treatments^{61,62}. Many features are described, including purpura (Fig. 4), ecchymoses, red macules, small erythematous or cyanotic lesions on hands and feet (Fig. 5), painful papules or nodules on the limbs, ears, neck or thighs and localized necrotic areas of the neck and anterior chest^{47,63-66}. These lesions are found in 2-2.6% of patients as the first sign of the disease and appear during its course in 3-3.9% of patients^{6,29}. Ecchymoses and purpura were detected in 14% of patients with LA³⁰.

LIVEDOID VASCULOPATHY AND ATROPHIE BLANCHE

Livedoid vasculopathy, otherwise known as livedoid vasculitis, segmental hyalinizing vasculitis or livedo reticularis with summer/winter ulceration, was originally described in 1967⁶⁷. It mostly affects young to middle-aged women and consists in focal purpuric painful lesions, usually on the legs and feet, that break down to form irregularly shaped ulcers. These heal slowly, leaving porcelain-white, stellate, atrophic scars surrounded by telangiectasia, haemosiderin deposition and hyperpigmentation, the so-called atrophie blanche⁶⁸. The pathogenesis of this condition is not fully understood but the histology shows a thrombotic process rather than vasculitis, hence the preferred term "vasculopathy"^{69,70}. It has been described as a sole entity and in association with other conditions, including APS. There are no large series documenting the prevalence of this finding but the association with APS has been well documented, thus allowing it into the cutaneous manifestations of this syndrome^{4,68,71-73}.

DEGOS'-LIKE LESIONS

Degos disease, also known as malignant atrophic



FIGURE 4. Cutaneous lesions on the legs clinically mimicking vasculitis – pseudovasculitic lesions on a female patient with APS

papulosis, is a rare multisystem vasoocclusive disorder affecting the skin, gastrointestinal tract and central nervous system. Skin lesions consist in crops of small painless yellowish papules over the trunk and extremities that develop a central depression and later a porcelain-white scar. It was first described in association with aPL by Engler *et al.* in 1984⁷⁴. This was not confirmed later by Assier *et al* who speculated that the patients with apparent Degos' disease had instead atrophie blanche lesions resembling those of Degos⁷⁵. It is suggested that patients with the benign form of this disease (limited to the skin) are more prone to have aPL⁷³. There are no data in the literature regarding the prevalence of this feature in APS nor of the prevalence of aPL in patients with Degos' disease.

PRIMARY ANETODERMA

Primary anetoderma is a rare disorder characterized by circumscribed depressions or patches of slack skin with an atrophied appearance (Fig. 6). Since its first description in association with APS in the early 90s, anetoderma has repeatedly been reported as an APS-related feature⁷⁶⁻⁸¹. It is thought to be an important skin sign for autoimmune disorders, including APS⁸². So far, in patients with SLE these lesions were always associated with aPL, being identified in 15% of these patients with LA but in none of the group where LA was absent^{52,82}.



FIGURE 5. Erythematous macules on the hands of a patient with APS

HISTOPATHOLOGY OF THE CUTANEOUS LESIONS

Although the heterogeneity of the aforementioned cutaneous findings, most of them have in common an important histopathologic feature: noninflammatory thrombosis of the dermal vessels^{4,29,32,73}. True vasculitis is not a feature. Early lesions usually show dermal edema, hemorrhage and occasional epidermal necrosis. Late-stage lesions may show reactive capillary proliferation, hemosiderin deposition and epidermal atrophy^{45,83-86}. Reactive angioendotheliomatosis has also been reported^{87,88}. Although nonspecific this is typical, highlighting the importance of a skin biopsy in many circumstances, especially when there is the need to exclude other conditions in order to select appropriate treatment. In the particular case of anetoderma, histopathologic examination shows elastic fibers depletion in the dermis under special stains, usually Verhoeff-van Gieson elastin stain^{28,73}.

MANAGEMENT OF CUTANEOUS MANIFESTATIONS

Diagnosing APS is not easy, particularly when we are dealing with cutaneous manifestations. When facing a patient with skin lesions suggestive of APS it is important to keep in mind that they are not included in the classification criteria. In fact, much has been debated when it comes to this fact. In the consensus statement a special consideration was given to LR, undoubtedly frequent but not specific¹⁴. The committee considered



FIGURE 6. Clinical features of anetoderma, with localized patches of slack skin with an atrophied appearance

that inclusion of LR as independent clinical criterion for definite APS would decrease diagnostic specificity, even though its association with APS is recognized. Other skin manifestations of APS are considered rare and none merits inclusion as a criterion. Another problem is how to classify cases with aPL and non-criteria clinical manifestations of APS, a common situation for dermatologists. “Probable APS”, “features associated with APS” or “non-criteria features of APS” are reasonable terms¹⁴. With these limitations in mind, one should know that although suggestive of the diagnosis of APS, a patient manifesting skin lesions consistent with the diagnosis and with serological evidence of circulating aPL still must meet additional clinical criteria. Such a patient can be classified as having probable APS but a definite diagnosis cannot be made⁸⁹. Recognizing the appropriateness of searching for aPL is another important issue since generalized searches are highly discouraged in order to avoid overdiagnosis and overtreatment. Testing should be limited to patients who have a significant probability of having APS²⁰. Diagnosis is more likely in a young patient, without other risk factors for thrombosis, presenting with an

unexplained cutaneous lesion that appears to be secondary to thrombosis or vascular occlusion. A skin biopsy is helpful when it is necessary to document vascular occlusion or exclude other conditions. In the absence of thrombosis APS cannot be diagnosed. When thrombosis is documented the presence of aPL make the diagnosis: if present the patient has APS, if absent only probable-APS can be assumed.

TREATMENT

Anticoagulation is the mainstay of the management of APS. In order to provide optimal care this should be individualized according to patient's clinical status and history of thrombotic events. The standard therapy is intravenous or subcutaneous heparin followed by warfarin. During pregnancy, low molecular weight heparin and aspirin should be used. In general, patients with the first venous thrombosis should have an INR of 2.0-3.0 and patients with arterial thrombosis or recurrent events should have an INR of > 3,0⁹⁰⁻⁹³. Additional vascular and thrombotic risk factors should be actively reduced. Treatment of catastrophic APS, although unsatisfactory, usually comprises combination therapy with high dose intravenous steroids and anticoagulation, intravenous gammaglobulin and repeated plasma exchanges^{8,9,90-93}. Duration and intensity of therapy remain controversial, so further trials are required to establish the optimal management of APS patients. In the meantime anticoagulation drugs are usually prescribed for life. Asymptomatic patients with circulating aPL or patients who do not display the formal classification criteria are usually treated with low dose aspirin or clopidogrel, although no evidence-based recommendations have been provided supporting this attitude. The same is also true for statins, antimalarials (especially in SLE) and angiotensin-converting enzyme inhibitors, recently suggested for prophylactic treatment⁹⁴⁻⁹⁷. In what concerns the treatment of patients with skin lesions, both dermatologic manifestations and the overall clinical situation should be considered. In the absence of randomized control trials, therapy for dermatologic manifestations remains empirical and no treatment has been systematically effective. Widespread cutaneous necrosis and digital gangrene are considered major thrombotic events requiring long-term anticoagulation treatment. If even so lesions continue to spread, plasma exchange, steroids and/or cytotoxic agents have been reported to

be successful^{29,48,49,73,98,99}. For other isolated skin presentations, combination therapy with aspirin and dipyridamol or pentoxifylline has been effective in some cases, but the potential benefit of this association still needs to be determined^{29,73,94-97}. Anyway, cutaneous lesions frequently recur or extend and in those circumstances anticoagulation is usually prescribed. When all of these fail, treatment may be very difficult and many alternatives have been proposed in the literature, with variable response, namely cyclophosphamide, azathioprine, rituximab, intravenous gamma globulins, fibrinolytic agents, sildenafil, androgenic anabolic steroids and autologous skin grafting^{29,54,55,73,98-100}.

CONCLUSION

Many cutaneous presentations have been described in association with APS. Although nonspecific and not included in the classification criteria, dermatologic findings are frequent and may be the presenting feature making them an important clue in the diagnosis of this disease. For that reason, it is important to be familiar with these cutaneous features and to recognize when APS investigation should be pursued. Being knowledgeable about APS, physicians can provide crucial information to uncover or confirm APS and early diagnosis will spare patients from more serious consequences of this disease.

CORRESPONDENCE TO

Teresa Pinto de Almeida
Serviço de Dermatologia, Hospital de Santo António
Centro Hospitalar do Porto
Porto, Portugal
E-mail: teresap.almeida@hotmail.com

REFERENCES

- Hughes GR. Thrombosis, abortion, cerebral disease and lupus anticoagulant. *Br Med J* 1983; 287: 1088-1089.
- Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. *J Rheumatol* 1986; 13: 486-489.
- Wong RC, Favloro EJ. Clinical features, diagnosis and management of the antiphospholipid syndrome. *Semin Thromb Hemost* 2008;34:295-304.
- Gibson GE, Su W, Pittelkow MR. Antiphospholipid syndrome and the skin. *J Am Acad Dermatol* 1997; 36: 970-982.
- Grob JJ, Bonerandi JJ. Cutaneous manifestations associated with the presence of the lupus anticoagulant. *J Am Acad Dermatol* 1986; 15: 211-219.
- Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum* 2002; 46: 1019-1027.
- Levine JS, Branch DW, Rauch J. The Antiphospholipid syndrome. *N Eng J Med* 2002; 346: 752-763.
- Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. *Medicine (Baltimore)* 1998; 77: 195-207.
- Stojanovich L, Marisavljevic D, Rovensky J et al. Clinical and laboratory features of the catastrophic antiphospholipid syndrome. *Clin Rev Allergy Immunol* 2009;36:74-79.
- Petri M. Epidemiology of the antiphospholipid antibody syndrome. *J Autoimmun* 2000; 15: 145-151.
- Jara LJ, Medina G, Vera-Lastra O et al. The impact of gender on clinical manifestations of primary antiphospholipid syndrome. *Lupus* 2005; 14: 607-612.
- Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999; 42: 1309-1311.
- Bart PA. When should consider antiphospholipid syndrome? *Rev Med Suisse* 2008; 16: 97-99.
- Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; 4: 295-306.
- Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. *Thromb Res* 2002; 108: 263-271.
- Tincani A, Allegri F, Sanmarco M et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum. *Thromb Haemost* 2001; 86: 575-583.
- Wong RC, Gillis D, Adelstein S et al. Consensus guidelines on anticardiolipin antibody testing and reporting. *Pathology* 2004; 36: 63-68.
- Reber G, Tincani A, Sanmarco M et al. Proposals for the measurement of anti-beta-2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. *J Thromb Haemost* 2004; 2: 1860-1862.
- Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. *Thromb Haemost* 1995; 74: 1185-1190.
- Pengo V, Banzato A, Bison E et al. Antiphospholipid syndrome: critical analysis of the diagnostic path. *Lupus* 2010; 19:428-431.
- Devreese K, Hoylaerts MF. Laboratory diagnosis of the Antiphospholipid syndrome: a plethora of obstacles to overcome. *Eur J Haematol* 2009; 83: 1-16.
- Tincani A, Filippini M, Scarsi M et al. European attempts for the standardization of the antiphospholipid antibodies. *Lupus* 2009; 18: 913-919.
- Pengo V, Biasiolo A. The risk of overdiagnosis of antiphospholipid antibody syndrome. *Thromb Haemost* 2001; 86: 933.
- Pengo V, Ruffatti A, Iliceto S. The diagnosis of the antiphospholipid syndrome. *Pathophysiol Haemost Thromb* 2006; 35: 175-180.
- Meroni PL, Tincani A, Alarcón-Riquelme ME et al. European forum on antiphospholipid antibodies: research in progress. *Lupus* 2009; 18: 924-929.
- Asherson RA, Khamashta MA, Ordi-Ros J et al. The primary antiphospholipid syndrome: major clinical and pathological features. *Medicine (Baltimore)* 1989; 68: 366-374.

27. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicentre study of 114 patients. *Am J Med* 1994; 96: 3-9.
28. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. *J Rheumatol* 1989; 16: 482-486.
29. Francès C, Niang S, Laffitte E et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. *Arthritis Rheum* 2005; 52: 1785-1793.
30. Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. *Br J Dermatol* 1989; 120: 419-429.
31. Cervera R, Asherson RA, Acevedo ML et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. *Ann Rheum Dis* 2004; 63: 1312-1317.
32. Diógenes MJ, Diógenes PC, Carneiro RM et al. Cutaneous manifestations associated with antiphospholipid antibodies. *Int J Dermatol* 2004; 43: 632-637.
33. Gibbs MB, English JC 3rd, Zirwas MJ. Livedo reticularis: an update. *J Am Acad Dermatol* 2005; 52: 1009-1019.
34. Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. *J Rheumatol* 2006; 33: 2379-2382.
35. Sneddon IB. Cerebrovascular lesions and livedo reticularis. *Br J Dermatol* 1965; 77: 180-185.
36. Levine SR, Langer SL, Albers JW, Welch KM. Sneddon s syndrome: an antiphospholipid antibodies syndrome. *Neurology* 1988; 38: 798-800.
37. Kalashnikova LA, Nasonov EL, Stoyanovich LZ et al. Sneddon s syndrome and the primary antiphospholipid syndrome. *Cerebrovasc Dis* 1994; 4: 76-82.
38. Merino AJ, Arenzana J. Primary antiphospholipid syndrome associated with Sneddon syndrome. *Rev Clin Esp*. 1992; 191: 226.
39. Vargas JA, Yebra M, Pascual ML, Manzano L. Sneddon syndrome and primary antiphospholipid syndrome: are they the same entity? *Med Clin (Barc)* 1990; 94: 597.
40. Francès C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. *J Autoimmun* 2000; 15: 139-143.
41. Sinharay R. Sneddon s syndrome: additional neurological feature on antiphospholipid (Hughes) syndrome. *Postgrad Med J* 2003; 79: 550.
42. Gantcheva M, Tsankov N. Livedo reticularis and cerebrovascular accidents (Sneddon s syndrome) as a clinical expression of antiphospholipid syndrome. *J Eur Acad Dermatol Venereol* 1999; 12: 157-160.
43. Francès C, Papo T, Wechsler B et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. *Medicine (Baltimore)* 1999; 78: 209-219.
44. Fetoni V, Grisoli M, Salmaggi A et al. Clinical and neuroradiological aspects of Sneddon s syndrome and primary antiphospholipid syndrome. A follow-up study. *Neurol Sci* 2000; 21: 157-164.
45. Robson K, Piette W. The presentation and differential diagnosis of cutaneous vascular occlusion syndromes. *Adv Dermatol* 1999; 15: 153-182.
46. Naldi L, Marchesi L, Finazzi G et al. Antiphospholipid antibodies and necrotizing purpura. *Dermatologica* 1990; 180: 272-275.
47. Sharkey MP, Daryanani II, Gillett MB, Jones SK. Localized cutaneous necrosis associated with the antiphospholipid syndrome. *Australas J Dermatol* 2002; 43: 218-220.
48. Jou IM, Liu MF, Chao SC. Widespread cutaneous necrosis associated with antiphospholipid syndrome. *Clin Rheumatol* 1996; 15: 394-398.
49. Abernethy ML, McGuinn JL, Callen JP. Widespread cutaneous necrosis as the initial manifestation of the antiphospholipid syndrome. *J Rheumatol* 1995; 22: 1380-1383.
50. Rossini J, Roverano S, Graf C, Paira S. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. *J Clin Rheumatol* 2002; 8: 326-331.
51. Creamer D, Hunt BJ, Black MM. Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome: a report of two cases. *Br J Dermatol* 2000; 142: 1199-1203.
52. Stephansson EA, Niemi KM, Jouhikainen T et al. Lupus anticoagulant and the skin. *Acta Derm Venereol (Stockh)* 1991; 71: 416-422.
53. Schlesinger IH, Farber GA. Cutaneous ulcerations resembling pyoderma gangrenosum in the primary antiphospholipid syndrome: a report of two additional cases and review of the literature. *J La State Med Soc* 1995; 147: 357-361.
54. Goldberg DP, Lewis VL Jr, Koenig WJ. Antiphospholipid antibody syndrome: a new cause of nonhealing skin ulcers. *Plast Reconstr Surg* 1995; 95: 837-841.
55. Gertner E, Lie JT. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome. *J Rheumatol* 1994; 21: 2159-2161.
56. Asherson RA, Cervera R, Shoenfeld Y. Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. *Ann N Y Acad Sci* 2007; 1108: 151-129.
57. Asherson RA, Cervera R, Klumb E et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. *Semin Arthritis Rheum*. 2008; 38: 124-131.
58. Frances C, Piette J, Saada V et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome. *Lupus* 1994; 3: 123-128.
59. Asherson R. Subungual splinter hemorrhages: a new sign of the antiphospholipid coagulopathy? *Ann Rheum Dis* 1990; 49: 268.
60. Kujic F, Lloyd M, Cuadrado MJ et al. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. *Clin Exp Rheumatol* 1995; 13: 327-331.
61. Carlson JA, Chen KR. Cutaneous pseudovasculitis. *Am J Dermatol* 2007; 29: 44-45.
62. Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical Spectrum. *Curr Rheumatol Rep* 2002; 4: 83-89.
63. Grob JJ, San Marco M, Aillaud MF et al. Unfading acral micro-livedo: a discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome. *J Am Acad Dermatol* 1991; 24: 53-58.
64. Asherson RA, Jacobelli S, Rosenberg H et al. Skin nodules and macules resembling vasculitis in the antiphospholipid syndrome – a report of two cases. *Clin Exp Dermatol* 1992; 17: 266-269.
65. Ishikawa O, Takahashi A, Tamura A, Miyachi Y. Cutaneous papules and nodules in the diagnosis of antiphospholipid syndrome. *Br J Dermatol* 1999; 140: 725-729.
66. Tomb R, Maalouf E, Attoui S. Cutaneous nodular lesions and antiphospholipid syndrome. *Ann Dermatol Venereol* 2008; 135: 484-487.

67. Bard JW, Winkelmann RK. Livedo vasculitis: segmental hyalinizing vasculitis of the dermis. *Arch Dermatol* 1967; 96: 489-499.
68. Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? *Br J Dermatol* 1999; 140: 131-135.
69. McCalmont CS, McCalmont TH, Jorizzo JL et al. Livedo vasculitis: vasculitis or thrombotic vasculopathy? *Clin Exp Dermatol* 1992; 17: 4-8.
70. Hairston B, Davis M, Pittelkow M et al. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. *Arch Dermatol* 2006; 142: 1413-1418.
71. Grasland A, Crickx B, Blanc M et al. Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies. *Ann Med Interne (Paris)* 2000; 151: 408-410.
72. Llamas P, Yebra M, Berrocal E et al. Idiopathic white atrophy and the primary antiphospholipid syndrome: a promise still unfulfilled. *Rev Clin Esp* 1996; 196: 342-343.
73. Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. *Hematol Oncol Clin N Am* 2008; 22: 67-77.
74. Englert H, Hawkes C, Boey M et al. Degos disease: association with anticardiolipin antibodies and lupus anticoagulant. *Br Med J* 1984; 289: 576.
75. Assier H, Chosidow O, Piette J et al. Absence of antiphospholipid and antiendothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases. *J Am Acad Dermatol* 1995; 33: 831-833.
76. Hodak E, Shamai Lubovitz O, David M et al. Immunologic abnormalities associated with primary anetoderma. *Arch Dermatol* 1992; 128: 799-803.
77. Disdier P, Harle J, Andrac L et al. Primary anetoderma associated with antiphospholipid syndrome. *J Am Acad Dermatol* 1994; 30: 133-134.
78. de Souza E, Christofoletti P, Cintra M. Anetoderma associated with primary antiphospholipid syndrome. *J Am Acad Dermatol* 2007; 56: 881-882.
79. Bilen N, Bayramgurler D, Sikar A et al. Anetoderma associated with antiphospholipid syndrome and systemic lupus erythematosus. *Lupus* 2003; 12: 714-716.
80. Hodak E, David M. Primary anetoderma and antiphospholipid antibodies-review of the literature. *Clin Rev Allergy Immunol* 2007; 32: 162-166.
81. Hodak E, Feuerman H, Moland Y et al. Primary anetoderma: a cutaneous sign of antiphospholipid antibodies. *Lupus* 2003; 12: 564-568.
82. Sparsa SA, Piette JC, Weschsler B et al. Anetoderma and its prothrombotic abnormalities. *J Am Acad Dermatol* 2003; 49: 1008-1012.
83. Lie J. Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis or both? *J Rheumatol* 1989; 16: 713-715.
84. Lie J. The distinction between vasculitis coincidental with one that is causally relates to the antiphospholipid syndrome. *Arthritis Rheum* 1992; 35: 15-40.
85. Lie J. Vasculitis in the antiphospholipid syndrome: culprit or consort? *J Rheumatol* 1994; 21: 397-399.
86. Cervera R, Asherson AR, Lie JT. Clinicopathologic correlation of antiphospholipid syndrome. *Semin Arthritis Rheum* 1995; 24: 262-272.
87. Creamer D, Black MM, Calonje E. Reactive angioendotheliomatosis in association with the antiphospholipid syndrome. *J Am Acad Dermatol* 2000; 42: 903-906.
88. Thai KE, Barret W, Kossard S. Reactive angioendotheliomatosis in the setting of antiphospholipid syndrome. *Australas J Dermatol* 2003; 44: 151-155.
89. Kriseman YL, Nash JW, Hsu S. Criteria for the diagnosis of antiphospholipid syndrome in patients presenting with dermatological symptoms. *J Am Acad Dermatol* 2007; 57: 112-115.
90. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. *J Autoimmun* 2009; 33: 92-98.
91. Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multi-systemic disease. *Clin Exp Rheumatol* 2009; 27: 668-677.
92. Brunner HI, Chan WS, Ginsberg JS, Fekdman BM. Longterm anticoagulation is preferable for patients with antiphospholipid syndrome - result of a decision analysis. *J Rheumatol* 2002; 29: 490-501.
93. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. *JAMA* 2006; 295: 1050-1057.
94. Gerosa M, Chighizola C, Meroni PL. Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). *Intern Emerg Med* 2008; 3: 201-203.
95. Erkan D, Yazici Y, Peterson MG et al. A cross sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. *Rheumatology* 2002; 41: 924-929.
96. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. *Arthritis Rheum* 2007; 56: 2382-2391.
97. Herenge T, Lambert M, Hachulla E et al. Influence of aspirin on the clinical outcomes of 103 antiphospholipid antibodies-positive patients. *Lupus* 2008; 17: 11-15.
98. Espinosa G, Cervera R. Recent trends in the management of antiphospholipid syndrome (Hughes syndrome). *Drugs Today (Barc)* 2010; 46: 39-47.
99. Asherson RA, Francès C, Iaccarino L et al. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. *Clin Exp Rheumatol* 2006; 24: 46-51.
100. Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. *Arthritis Rheum* 2003; 48: 3004-3008.